Trial Profile
A Phase 2 Trial of Alemtuzumab-Ofatumumab Combination in Previously Untreated Symptomatic Chronic Lymphocytic Leukemia
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 29 Mar 2024
Price :
$35
*
At a glance
- Drugs Alemtuzumab (Primary) ; Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 25 Mar 2024 Planned End Date changed from 1 May 2023 to 1 May 2027.
- 01 Nov 2022 Results published in the Leukemia Research
- 04 Oct 2022 Planned End Date changed from 1 May 2022 to 1 May 2023.